There is no Medicare coverage determination addressing this service; therefore, the Company policy is applicable.
Subject to the terms and conditions of the applicable Evidence of Coverage, bioimpedance for the detection of lymphedema is not eligible for payment under the medical benefits of the Company's Medicare Advantage products because the service is considered experimental/investigational and, therefore, not covered.
Services that are experimental/investigational are excluded for the Company's Medicare Advantage products. Therefore, they are not eligible for reimbursement consideration.
US FOOD AND DRUG ADMINISTRATION (FDA)
There are numerous devices approved by the FDA for bioimpedance for the detection of lymphedema.